Fresh Approaches to RT Improve Outcomes in Retroperitoneal Sarcoma
July 15th 2019Each year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.
Borghaei Discusses Long-Term Pembrolizumab NSCLC Data, Broadening Clinical Trial Eligibility
Hossein Borghaei, MD, highlights long-term single-agent pembrolizumab (Keytruda) data and the overall state of immunotherapy in non–small cell lung cancer, as well as the prospect of making clinical trial eligibility less restrictive.
Fox Chase Investigates Screening Methods to Avoid Unnecessary Radical Cystectomy
March 28th 2019Currently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.
AHCT Consolidation Improves PFS in Younger Patients With Mantle Cell Lymphoma
January 17th 2019Within 6 months of receiving induction chemotherapy, consolidation treatment with autologous hematopoietic cell transplantation correlated with a significant improvement in progression-free survival in younger, fit patients with mantle cell lymphoma.
Dr. Borghaei on the Current Landscape of Immunotherapy in NSCLC
October 30th 2018Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the current landscape of immunotherapy in non–small cell lung cancer (NSCLC).
Dr. Borghaei on Molecular Profiling in Lung Cancer
October 12th 2018Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses molecular profiling in lung cancer.
Dr. Borghaei on the FDA Approval of Nivolumab in Small Cell Lung Cancer
August 17th 2018Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.
Dr. Bauman on Treatments for Patients With BRAF-Mutant NSCLC
July 4th 2018Jessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).
It's Not Quite Prime Time for Up-Front Genomic Sequencing in Early-Stage CRC
June 11th 2018Although testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.
Dr. Uzzo Discusses the Role of Surgery in Kidney Cancer
October 26th 2017Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the role of surgery in kidney cancer.
Dr. Uzzo on Unmet Needs in Kidney Cancer
October 4th 2017Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses pressing unmet needs for patients with kidney cancer.
Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer
August 15th 2017Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.
Dr. Borghaei on Reporting Immunotherapy-Related AEs in Lung Cancer
January 20th 2017Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.
Efforts Continue to Refine Use of Checkpoint Inhibitors in NSCLC
October 5th 2016Hossein Borghaei, DO, provides additional insight on checkpoint inhibitors, determining patient selection, and how these therapies will continue to significantly impact the treatment landscape in non–small cell lung cancer for years to come.
Expert Discusses Immense Impact of Immunotherapy in GU Cancers
September 21st 2016Elizabeth Plimack, MD, discusses some of the most impressive advancements with immunotherapy agents in the fields of renal cell carcinoma and bladder cancer, as well as remaining questions with the use of these treatments.